Thursday, May 2, 2013

Alembic Pharmaceuticals Limited announces its results for the Year ended 31st March 2013


 


Highlights:-

Quarter ended 31st March 2013
• Net Profit after tax up by 115% at Rs. 43.65 crores against Rs. 20.31 crores in corresponding quarter in last  year
• Profit before tax up by 105% at Rs. 55.18 crores against  Rs. 26.94 crores in corresponding quarter in last year
• For the quarter net sales up 11% at Rs 378.36 crores  against Rs. 342.30 crores in corresponding quarter last  year

Year ended 31st March 2013
• Profit after tax up by 27% at Rs. 165.25 crores against Rs. 130.14 crores in last year
• Profit before tax up by 28% at Rs. 206.35 crores against  Rs. 160.99 crores in last year
• EBIDTA margins 16.57% at Rs. 251.96 crores against 14.97% at Rs. 219.43 crores in last year
• Net sales grew by 4% for full year at Rs. 1526.00 crores  against Rs. 1467.89 crores

About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3600 are well recognized by doctors and patients. Information about the company can be found at www.alembicindia.com